Suchergebnisse - "Arthritis, Rheumatoid"

PubPharm (247)

61

After JAK inhibitor failure : to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries

enthalten in: Annals of the rheumatic diseases | 2023

von Pombo-Suarez, M. | Sanchez-Piedra, C. | Gómez-Reino, J. | +20

62

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

enthalten in: RMD open | 2023

von Burmester, G. | Cohen, S. | Winthrop, K. | +11

63

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab : a nationwide cohort study

enthalten in: Annals of the rheumatic diseases | 2023

von Hoisnard, L. | Pina Vegas, L. | Dray-Spira, R. | +3

ErratumIn: Ann Rheum Dis. 2023 Nov;82(11):e222. - PMID 37827705

64

Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?

enthalten in: Annals of the rheumatic diseases | 2023

von Pope, J. | Fleischmann, R.

65

American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis : 2022 revision

enthalten in: Annals of the rheumatic diseases | 2023

von Studenic, P. | Aletaha, D. | de Wit, M. | +5

66

Efficacy, duration of use and safety of glucocorticoids : a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

enthalten in: Annals of the rheumatic diseases | 2023

von Bergstra, S. | Sepriano, A. | Kerschbaumer, A. | +14

67

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease : a post hoc analysis from ORAL Surveillance

enthalten in: Annals of the rheumatic diseases | 2023

von Charles-Schoeman, C. | Buch, M. | Dougados, M. | +13

68

Interstitial lung disease in rheumatoid arthritis : incidence, prevalence and related drug prescriptions between 2007 and 2020

enthalten in: RMD open | 2023

von Albrecht, K. | Strangfeld, A. | Marschall, U. | +1

69

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2022 update

enthalten in: Annals of the rheumatic diseases | 2023

von Smolen, J. | Landewé, R. | Bergstra, S. | +45

ErratumIn: Ann Rheum Dis. 2023 Mar;82(3):e76. - PMID 36764818

70

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

enthalten in: Annals of the rheumatic diseases | 2023

von Dougados, M. | Charles-Schoeman, C. | Szekanecz, Z. | +13